Back

How low can early introduction of evidence based heart failure medications drive readmission rates?

21 May 2023 (09:00 - 10:08)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - pharmacotherapy 3 Pharmacotherapy HFA Premium Access Heart Failure 2023 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Talia Caspi

Homerton University Hospital, London (United Kingdom of Great Britain & Northern Ireland)

6 More presentations in this session

Presentation thumbnail
Heart rate management practices in HFrEF among Indian cardiologists: Role of beta-blocker and ivabradine-based therapy
Doctor V. Kolapkar (Thane, IN)
Abstract Slides
Presentation thumbnail
Myocardial ketone body oxidation underlies the salutary effects of SGLT2 inhibitor treatment in heart failure
Ms S. Voorrips (Groningen, NL)
Abstract Slides
Presentation thumbnail
The effect of add-on Ivabradine in patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials and real-world data
Doctor C. Liao (Tainan, TW)
Abstract Slides
Presentation thumbnail
How much can ejection fraction be improved in patients with heart failure with reduced ejection fraction (HFrEF) by the early introduction of evidence-based heart failure medication?
Doctor J. White (London, GB)
Abstract Slides
Presentation thumbnail
Early treatment of heart failure: a non-interventional observational study programme of patients with heart failure and initiated on dapagliflozin (EVOLUTION HF)
Doctor S. Adamsson Eryd (Gothenburg, SE)
Abstract Slides

Access the full session

Session thumbnail
ePosters in chronic heart failure - pharmacotherapy 3

The Event

Event poster

Heart Failure 2023

21 May 2023 09:00 CET
You may be interested in
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios
thumbnail
Congress Session
Meet the Experts: summation of the science - treatment of chronic heart failure in 2023
thumbnail
Congress Session
Acute heart failure therapies: from clinical trials to clinical practice

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources